FEV1, PEF, PD20 methacholine, symptom scores, and terbutaline dose at baseline and end of study in the β agonist reduction group and controls
| β agonist reduction group | Control group | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | End of study2-150 | Baseline | End of study2-150 | ||||
| Mean (SD) FEV1 (l) | 2.5 (0.6) | 2.5 (0.6) | 2.4 (0.8) | 2.5 (0.7) | |||
| Mean (SD) FEV1 (% predicted) | 73.2 (12.8) | 69.0 (15.8) | |||||
| Mean (SD) am PEF (l/min) | 415 (93) | 411 (97) | 370 (93) | 370 (88) | |||
| Mean (SD) pm PEF (l/min) | 444 (112) | 432 (116) | 402 (88) | 399 (85) | |||
| Geometric mean (log SD) PD20(μmol) | 1.2 (0.6) | 3.2 (0.7) | 0.6 (0.7) | 1.17 (0.6) | |||
| Median (IQR) symptom score | 0 (0–1) | 0.25 (0–0.8) | 1 (1–1.9) | 1 (0.4–1.5) | |||
| Median (range) terbutaline dose (μg/day) | 2500 (2000–4750) | 500 (0–2500) | 3000 (2000–7000) | 2250 (1750–5750) | |||
↵2-150 End of study = mean of weeks 11 and 12 values; FEV1 = forced expiratory volume in one second; PEF = peak expiratory flow rate; PD20 = dose of methacholine producing a 20% fall in FEV1, SD = standard deviation, IQR = interquartile range.